Ind. Code § 25-26-24-1 "Board"
Sec. 1. As used in this chapter, "board" refers to the Indiana board of pharmacy.
As added by P.L.51-2019, SEC.8.
Ind. Code ch. 25-26-24
Ind. Code ch. 25-26-24
in effectInd. Code § 25-26-24-2 "Committee"
Sec. 2. As used in this chapter, "committee" refers to the INSPECT oversight committee established by section 24 of this chapter.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-2.5 "Controlled substance"
Sec. 2.5. As used in this chapter, "controlled substance" has the meaning set forth in IC 35-48-1.1-7. The term includes gabapentin.
As added by P.L.246-2019, SEC.21 and P.L.264-2019, SEC.10. Amended by P.L.186-2025, SEC.142.
Ind. Code § 25-26-24-3 "Dispense"
Sec. 3. As used in this chapter, "dispense" means to deliver a controlled substance to an ultimate user or research subject by or pursuant to the lawful order of a practitioner and includes the prescribing, administering, packaging, labeling, or compounding necessary to prepare the substance for that delivery.
As added by P.L.51-2019, SEC.8. Amended by P.L.133-2026, SEC.1.
Ind. Code § 25-26-24-4 "Ephedrine"
Sec. 4. As used in this chapter, "ephedrine" includes only ephedrine that is dispensed pursuant to a prescription or drug order.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-5 "Exception report"
Sec. 5. As used in this chapter, "exception report" means a record of data concerning:
(1) a practitioner practicing a particular specialty or field of health care;
(2) a dispenser doing business in a particular location; or
(3) a recipient;
that indicates dispensing or receiving of controlled substances outside norms for dispensing or receiving controlled substances established by the board under this chapter.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-6 "Identification number"
Sec. 6. As used in this chapter, "identification number" refers to the following:
(1) The unique number contained on any of the following:
(A) A valid driver's license of a recipient or a recipient's representative issued under Indiana law or the law of any other state.
(B) A recipient's or a recipient representative's valid military identification card.
(C) A valid identification card of a recipient or a recipient's representative issued by:
(i) the bureau of motor vehicles as described in IC 9-24-16-3; or
(ii) any other state and that is similar to the identification card issued by the bureau of motor vehicles.
(D) A valid photo exempt identification card of a recipient or a recipient's representative issued by:
(i) the bureau of motor vehicles as described in IC 9-24-16.5-1; or
(ii) any other state and that is similar to the photo exempt identification card issued by the bureau of motor vehicles.
(E) If the recipient is an animal:
(i) the valid driver's license issued under Indiana law or the law of any other state;
(ii) the valid military identification card; or
(iii) the valid identification card issued by the bureau of motor vehicles and described in IC 9-24-16-3, a valid photo exempt identification card issued by the bureau of motor vehicles as described in IC 9-24-16.5-1, or a valid identification card or photo exempt identification card of similar description that is issued by any other state;
of the animal's owner.
(2) The identification number or phrase designated by the central repository.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-7 "INSPECT"
Sec. 7. As used in this chapter, "INSPECT" means the Indiana scheduled prescription electronic collection and tracking program established by IC 25-1-13-4.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-8 "Interoperability"
Sec. 8. As used in this chapter, "interoperability" refers to the INSPECT program electronically sharing reported information with another state concerning the dispensing of a controlled substance:
(1) to a recipient who resides in the other state; or
(2) prescribed by a practitioner whose principal place of business is located in another state.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-9 "Pain management clinic"
Sec. 9. (a) As used in this chapter, "pain management clinic" means a publicly or privately owned facility that primarily engages in the treatment of pain or pain management through prescribing controlled substances.
(b) The term does not include the following:
(1) A hospital licensed under IC 16-21, including a facility owned by the hospital or an office of a hospital employed physician.
(2) An accredited school, college, university, or other educational institution or program that is related to providing instruction to individuals preparing to practice as a dentist, physician, physician assistant, nurse, optometrist, podiatrist, or veterinarian.
(3) A hospice program licensed under IC 16-25-3.
(4) An ambulatory outpatient surgical center licensed under IC 16-21-2.
(5) A long term care facility licensed under IC 16-28-2.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-10 "Patient"
Sec. 10. As used in this chapter, "patient" means an individual who has requested or received health care services from a provider for the examination, treatment, diagnosis, or prevention of a physical or mental condition.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-11 "Practitioner"
Sec. 11. As used in this chapter, "practitioner" means a physician, dentist, veterinarian, podiatrist, nurse practitioner, scientific investigator, pharmacist, hospital, or other institution or individual licensed, registered, or otherwise permitted to distribute, dispense, conduct research with respect to, or administer a controlled substance in the course of professional practice or research in the United States.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-12 "Prescription"
Sec. 12. As used in this chapter, "prescription" means an order for medication that is dispensed to or for a recipient. The term does not include an order for medication that is dispensed for immediate administration to the recipient.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-12.5 "Prescription drug monitoring program data"
Sec. 12.5. "Prescription drug monitoring program data", for purposes of section 19 of this chapter, means the following:
(1) Information received under section 17 of this chapter, including clinical or required alerts as defined by the board.
(2) Any other information determined by the board, including:
(A) a report concerning controlled substance poisonings or overdoses; and
(B) information concerning participation in an opioid treatment program (as defined in IC 12-7-2-135.6).
As added by P.L.133-2026, SEC.2.
Ind. Code § 25-26-24-13 "Pseudoephedrine"
Sec. 13. As used in this chapter, "pseudoephedrine" includes only pseudoephedrine that is dispensed pursuant to a prescription or drug order.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-14 "Recipient"
Sec. 14. As used in this chapter, "recipient" means an individual for whom a controlled substance is dispensed.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-15 "Recipient representative"
Sec. 15. As used in this chapter, "recipient representative" means the individual to whom a controlled substance is dispensed if the recipient is either less than eighteen (18) years of age or unavailable to receive the controlled substance.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-16 "State"
Sec. 16. As used in this chapter, "state" means any state of the United States or the District of Columbia.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-17 Program components; recommendations; retail pharmacy
Sec. 17. (a) Except as provided in section 17.5 of this chapter, the board shall provide for an ephedrine, pseudoephedrine, and controlled substance prescription monitoring program that includes the following components:
(1) Each time ephedrine, pseudoephedrine, or a controlled substance designated by the board under IC 35-48-2-5 through IC 35-48-2-10 is dispensed, the dispenser shall transmit to the INSPECT program the following information:
(A) The ephedrine, pseudoephedrine, or controlled substance recipient's name.
(B) The ephedrine, pseudoephedrine, or controlled substance recipient's or the recipient representative's identification number or the identification number or phrase designated by the INSPECT program.
(C) The ephedrine, pseudoephedrine, or controlled substance recipient's date of birth.
(D) The national drug code number of the ephedrine, pseudoephedrine, or controlled substance dispensed.
(E) The date the ephedrine, pseudoephedrine, or controlled substance is dispensed.
(F) The quantity of the ephedrine, pseudoephedrine, or controlled substance dispensed.
(G) The number of days of supply dispensed.
(H) The dispenser's United States Drug Enforcement Agency registration number.
(I) The prescriber's United States Drug Enforcement Agency registration number.
(J) An indication as to whether the prescription was transmitted to the pharmacist orally or in writing.
(K) Other data required by the board.
(2) The information required to be transmitted under this section must be transmitted not more than twenty-four (24) hours after the date on which ephedrine, pseudoephedrine, or a controlled substance is dispensed. However, if the dispenser's pharmacy is closed the day following the dispensing, the information must be transmitted by the end of the next business day. A dispenser who is also authorized to prescribe is required only to report actual dispensations within twenty-four (24) hours of the dispensation.
(3) A dispenser shall transmit the information required under this section by:
(A) uploading to the INSPECT website; or
(B) another electronic method that meets specifications prescribed by the board.
(4) The board may require that prescriptions for ephedrine, pseudoephedrine, or controlled substances be written on a one (1) part form that cannot be duplicated. However, the board may not apply such a requirement to prescriptions filled at a pharmacy with a Category II permit (as described in IC 25-26-13-17) and operated by a hospital licensed under IC 16-21, or prescriptions ordered for and dispensed to bona fide enrolled patients in facilities licensed under IC 16-28. The board may not require multiple copy prescription forms for any prescriptions written. The board may not require different prescription forms for any individual drug or group of drugs. Prescription forms required under this subdivision must be approved by the Indiana board of pharmacy created by IC 25-26-13-3.
(5) The costs of the program.
(6) As part of the information to be completed in the data base and, if available, an entry where a dispenser indicates that a patient is participating in a pain management contract with a designated practitioner.
(b) The board shall consider the recommendations of the committee concerning the INSPECT program.
(c) This subsection applies only to a retail pharmacy. A pharmacist, pharmacy technician, or person authorized by a pharmacist to dispense ephedrine, pseudoephedrine, or a controlled substance may not dispense ephedrine, pseudoephedrine, or a controlled substance to a person who is not personally known to the pharmacist, pharmacy technician, or person authorized by a pharmacist to dispense a controlled substance unless the person taking possession of the ephedrine, pseudoephedrine, or controlled substance provides documented proof of the person's identification to the pharmacist, pharmacy technician, or person authorized by a pharmacist to dispense ephedrine, pseudoephedrine, or a controlled substance.
As added by P.L.51-2019, SEC.8. Amended by P.L.17-2021, SEC.1; P.L.133-2026, SEC.3.
Ind. Code § 25-26-24-17.5 Exceptions to requirement to transmit information to program
Sec. 17.5. A dispenser is not required to transmit information required under section 17 of this chapter to the INSPECT program in the following circumstances:
(1) A drug is administered directly to a patient.
(2) A drug is dispensed by a veterinary practitioner, if the quantity dispensed is not more than a seventy-two (72) hour supply of a controlled substance listed in schedule II, III, IV, or V as set forth in IC 35-48-3-9.
As added by P.L.133-2026, SEC.4.
Ind. Code § 25-26-24-18 Program requirements; execution of contracts; data; funding
Sec. 18. (a) The INSPECT program must do the following:
(1) Create a data base for information required to be transmitted under section 17 of this chapter in the form required under rules adopted by the board, including search capability for the following:
(A) An ephedrine, pseudoephedrine, or a controlled substance recipient's name.
(B) An ephedrine, pseudoephedrine, or a controlled substance recipient's or recipient representative's identification number.
(C) An ephedrine, pseudoephedrine, or a controlled substance recipient's date of birth.
(D) The national drug code number of ephedrine, pseudoephedrine, or a controlled substance dispensed.
(E) The dates ephedrine, pseudoephedrine, or a controlled substance are dispensed.
(F) The quantities of ephedrine, pseudoephedrine, or controlled substance dispensed.
(G) The number of days of supply dispensed.
(H) A dispenser's United States Drug Enforcement Agency registration number.
(I) A prescriber's United States Drug Enforcement Agency registration number.
(J) Whether a prescription was transmitted to the pharmacist orally or in writing.
(K) An ephedrine, pseudoephedrine, or a controlled substance recipient's method of payment for the ephedrine, pseudoephedrine, or controlled substance dispensed.
To the extent considered appropriate by the board, the data base must be interoperable with other similar registries operated by federal and state governments.
(2) Provide the board with continuing twenty-four (24) hour a day online access to the data base.
(3) Secure the information collected and the data base maintained against access by unauthorized persons.
(b) The board may not execute a contract with a vendor designated by the board to perform any function associated with the administration of the INSPECT program, unless the contract has been approved by the committee.
(c) The INSPECT program may gather prescription data from the Medicaid retrospective and prospective drug utilization review (DUR) program established under IC 12-15-35.
(d) The board may accept and designate grants, public and private financial assistance, and licensure fees to provide funding for the INSPECT program.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-18.5 Patient consent
Sec. 18.5. Before reporting patient information to the INSPECT program, an opioid treatment program shall comply with 42 CFR 2.36 and 42 CFR 2.31 in obtaining patient consent.
As added by P.L.133-2026, SEC.5.
Ind. Code § 25-26-24-19 Confidentiality; disclosure; release of information; applicants; statistical reports; data base; immunity
Sec. 19. (a) Information received by the INSPECT program under section 17 of this chapter is confidential.
(b) The board shall carry out a program to protect the confidentiality of the information described in subsection (a). The board may disclose the information to another person only under subsection (c), (d), (g), or (s).
(c) The board may disclose confidential information described in subsection (a) to any person who is authorized to engage in receiving, processing, or storing the information.
(d) Except as provided in subsections (e) and (f), the board may release confidential information described in subsection (a) to the following persons:
(1) A member of the board or another governing body that licenses practitioners and is engaged in an investigation, an adjudication, or a prosecution of a violation under any state or federal law that involves ephedrine, pseudoephedrine, or a controlled substance.
(2) An investigator for the consumer protection division of the office of the attorney general, a prosecuting attorney, the attorney general, a deputy attorney general, or an investigator from the office of the attorney general, who is engaged in:
(A) an investigation;
(B) an adjudication; or
(C) a prosecution;
of a violation under any state or federal law that involves ephedrine, pseudoephedrine, or a controlled substance.
(3) A law enforcement officer who is an employee of:
(A) a local, state, or federal law enforcement agency; or
(B) an entity that regulates ephedrine, pseudoephedrine, or controlled substances or enforces ephedrine, pseudoephedrine, or controlled substances rules or laws in another state;
that is certified to receive ephedrine, pseudoephedrine, or controlled substance prescription drug information from the INSPECT program.
(4) A practitioner or practitioner's agent certified to receive information from the INSPECT program.
(5) An ephedrine, pseudoephedrine, or controlled substance monitoring program in another state with which Indiana has established an interoperability agreement.
(6) The state toxicologist.
(7) A certified representative of the Medicaid retrospective and prospective drug utilization review program.
(8) A substance abuse assistance program for a licensed health care provider who:
(A) has prescriptive authority under this title; and
(B) is participating in the assistance program.
(9) An individual who holds a valid temporary medical permit issued under IC 25-22.5-5-4 or a noneducational commission for foreign medical graduates certified graduate permit issued under IC 25-22.5-5-4.6.
(10) A county coroner conducting a medical investigation of the cause of death.
(11) The management performance hub established by IC 4-3-26-8.
(12) The state epidemiologist under the Indiana department of health.
(13) A supervisor of the department of child services who is engaged in:
(A) an investigation; or
(B) an adjudication;
of child abuse or neglect.
(e) Information provided to a person under:
(1) subsection (d)(3) is limited to information:
(A) concerning an individual or proceeding involving the unlawful diversion or misuse of a schedule II, III, IV, or V controlled substance; and
(B) that will assist in an investigation or proceeding;
(2) subsection (d)(4) may be released only for the purpose of:
(A) providing medical or pharmaceutical treatment; or
(B) evaluating the need for providing medical or pharmaceutical treatment to a patient; and
(3) subsection (d)(11) must be released to the extent disclosure of the information is not prohibited by applicable federal law.
(f) Before the board releases confidential information under subsection (d), the applicant must be approved by the INSPECT program in a manner prescribed by the board.
(g) The board may release to:
(1) a member of the board or another governing body that licenses practitioners;
(2) an investigator for the consumer protection division of the office of the attorney general, a prosecuting attorney, the attorney general, a deputy attorney general, or an investigator from the office of the attorney general; or
(3) a law enforcement officer who is:
(A) authorized by the state police department to receive ephedrine, pseudoephedrine, or controlled substance prescription drug information; and
(B) approved by the board to receive the type of information released;
confidential information generated from computer records that identifies practitioners who are prescribing or dispensing large quantities of a controlled substance.
(h) The information described in subsection (g) may not be released until it has been reviewed by:
(1) a member of the board who is licensed in the same profession as the prescribing or dispensing practitioner identified by the data; or
(2) the board's designee;
and until that member or the designee has certified that further investigation is warranted. However, failure to comply with this subsection does not invalidate the use of any evidence that is otherwise admissible in a proceeding described in subsection (i).
(i) An investigator or a law enforcement officer receiving confidential information under subsection (c), (d), or (g) may disclose the information to a law enforcement officer or an attorney for the office of the attorney general for use as evidence in the following:
(1) A proceeding under IC 16-42-20.
(2) A proceeding under any state or federal law.
(3) A criminal proceeding or a proceeding in juvenile court.
(j) The board may compile statistical reports from the information described in subsection (a). The reports must not include information that identifies any practitioner, ultimate user, or other person administering ephedrine, pseudoephedrine, or a controlled substance. Statistical reports compiled under this subsection are public records.
(k) Except as provided in subsections (q) and (r), and in addition to any requirements provided in IC 25-22.5-13, the following practitioners shall obtain information about a patient from the data base either directly or through the patient's integrated health record before prescribing an opioid or benzodiazepine to the patient:
(1) A practitioner who has had the information from the data base integrated into the patient's electronic health records.
(2) A practitioner who provides services to the patient in:
(A) the emergency department of a hospital licensed under IC 16-21; or
(B) a pain management clinic.
(3) Beginning January 1, 2020, a practitioner who provides services to the patient in a hospital licensed under IC 16-21.
(4) Beginning January 1, 2021, all practitioners.
However, a practitioner is not required to obtain information about a patient who is subject to a pain management contract from the data base more than once every ninety (90) days.
(l) A practitioner who checks the INSPECT program either directly through the data base or through the patient's integrated health record for the available data on a patient is immune from civil liability for an injury, death, or loss to a person solely due to a practitioner:
(1) seeking information from the INSPECT program; and
(2) in good faith using the information for the treatment of the patient.
The civil immunity described in this subsection does not extend to a practitioner if the practitioner receives information directly from the INSPECT program or through the patient's integrated health record and then negligently misuses this information. This subsection does not apply to an act or omission that is a result of gross negligence or intentional misconduct.
(m) The board may review the records of the INSPECT program. If the board determines that a violation of the law may have occurred, the board shall notify the appropriate law enforcement agency or the relevant government body responsible for the licensure, regulation, or discipline of practitioners authorized by law to prescribe controlled substances.
(n) A practitioner who in good faith discloses information based on a report from the INSPECT program either directly through the data base or through the patient's integrated health record to a law enforcement agency is immune from criminal or civil liability. A practitioner that discloses information to a law enforcement agency under this subsection is presumed to have acted in good faith.
(o) A practitioner's agent may act as a delegate and check INSPECT program reports on behalf of the practitioner.
(p) A patient may access a report from the INSPECT program that has been included in the patient's medical file by a practitioner.
(q) A practitioner is not required under subsection (k) to obtain information about a patient from the data base or through the patient's integrated health record before prescribing an opioid or benzodiazepine if any of the following apply:
(1) The practitioner has obtained a waiver from the board because the practitioner does not have access to the Internet at the practitioner's place of business.
(2) The patient is:
(A) recovering; or
(B) in the process of completing a prescription that was prescribed by another practitioner;
while still being treated as an inpatient or in observation status.
(3) The data base described in section 18 of this chapter is suspended or is not operational if the practitioner documents in writing or electronically the date and time in the patient's medical record that the practitioner, dispenser, or delegate attempted to use the data base.
(r) A practitioner is not required under subsection (k) to obtain information about a patient from the data base or through the patient's integrated health record before prescribing an opioid or benzodiazepine if the patient is enrolled in a hospice program (as defined in IC 16-25-1.1-4).
(s) The board may disclose prescription drug monitoring program data to a representative of the Indiana department of health and the office of the secretary of family and social services to do the following:
(1) Aid in an active investigation concerning a controlled substance.
(2) Prevent overdose events.
As added by P.L.51-2019, SEC.8. Amended by P.L.56-2023, SEC.241; P.L.233-2023, SEC.5; P.L.81-2025, SEC.1; P.L.133-2026, SEC.6.
Ind. Code § 25-26-24-19.5 Release of INSPECT information to a veterinarian
Sec. 19.5. A practitioner who is a veterinarian and who is treating an animal may obtain information about:
(1) the owner of the animal; or
(2) the individual to whom an opioid or benzodiazepine will be dispensed for the animal;
from the data base before prescribing an opioid or benzodiazepine for the animal.
As added by P.L.211-2019, SEC.38.
Ind. Code § 25-26-24-20 Certification requirement
Sec. 20. A practitioner who is permitted to distribute, dispense, prescribe, conduct research with respect to, or administer ephedrine, pseudoephedrine, or a controlled substance in the course of the practitioner's professional practice or research in the United States must be certified under section 19(d)(4) of this chapter to receive information from the INSPECT program.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-21 Review by governing board of dissemination of exception reports; investigation
Sec. 21. (a) Each board described in IC 25-0.5-11-1 that regulates a health care provider that prescribes or dispenses prescription drugs may review and act upon the unsolicited dissemination of exception reports under section 19 of this chapter.
(b) Upon receipt of an exception report, the board may:
(1) send the exception report to a law enforcement agency for purposes of an investigation; or
(2) send the exception report to the office of the attorney general for purposes of an investigation.
(c) If the board sends an exception report as described in subsection (b)(1) or (b)(2), it shall ensure compliance with section 19 of this chapter.
(d) Notwithstanding subsection (a), the board may disseminate exception reports to prescribers and dispensers specific to recipients.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-22 Rules; standards; intervention and treatment
Sec. 22. (a) The board shall adopt rules under IC 4-22-2 to implement this chapter, including the following:
(1) Information collection and retrieval procedures for the INSPECT program, including the controlled substances to be included in the program required under section 17 of this chapter.
(2) Design for the creation of the data base required under section 18 of this chapter.
(3) Requirements for the development and installation of online electronic access by the board to information collected by the INSPECT program.
(4) Identification of emergency situations or other circumstances in which a practitioner may prescribe, dispense, and administer a prescription drug specified in section 17 of this chapter without a written prescription or on a form other than a form specified in section 17(a)(4) of this chapter.
(5) Requirements for a practitioner providing treatment for a patient at an opioid treatment program operating under IC 12-23-18 to check the INSPECT program:
(A) before initially prescribing ephedrine, pseudoephedrine, or a controlled substance to a patient; and
(B) periodically during the course of treatment that uses ephedrine, pseudoephedrine, or a controlled substance.
(b) The board may:
(1) set standards for education courses for individuals authorized to use the INSPECT program;
(2) identify treatment programs for individuals addicted to controlled substances monitored by the INSPECT program; and
(3) work with impaired practitioner associations to provide intervention and treatment.
(c) The executive director of the Indiana professional licensing agency may hire a person to serve as the director of the INSPECT program, with the approval of the chairperson of the board.
(d) The board shall do the following:
(1) Establish a procedure for a practitioner to request a waiver from the requirements of section 19(k) of this chapter if the practitioner does not have access to the Internet at the practitioner's place of business.
(2) Review a practitioner's written request for a waiver from the requirements of section 19(k) of this chapter and determine whether the practitioner should be granted a waiver.
(3) Upon determination by the board under subdivision (2) that a practitioner should be granted a waiver under this subsection, issue the practitioner a waiver.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-23 Fund
Sec. 23. (a) The controlled substances data fund is established to fund the administration of the INSPECT program. The fund shall be administered by the Indiana professional licensing agency.
(b) Expenses of administering the fund shall be paid from money in the fund. The fund consists of grants, public and private financial assistance, and the controlled substances registration fees imposed under rules adopted under IC 35-48-3-1.
(c) The treasurer of state shall invest the money in the fund not currently needed to meet the obligations of the fund in the same manner as other public money may be invested.
(d) Money in the fund at the end of a state fiscal year does not revert to the state general fund.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-24 Committee; members; recommendations; meetings; term; reporting requirement
Sec. 24. (a) The INSPECT oversight committee is established.
(b) The committee consists of the following members:
(1) The president of the board or the president's designee, who shall serve as the chairperson of the committee.
(2) The commissioner of the Indiana department of health or the commissioner's designee.
(3) The superintendent of the state police department or the superintendent's designee.
(4) The attorney general or the attorney general's designee.
(5) Two (2) lay members who are authorized users of the INSPECT program appointed by the president pro tempore of the senate, not more than one (1) of whom may be affiliated with the same political party.
(6) Two (2) lay members who are authorized users of the INSPECT program appointed by the speaker of the house of representatives, not more than one (1) of whom may be affiliated with the same political party.
(c) The committee shall provide recommendations to the board concerning the implementation of policies, standards, and rules that promote the effective operation of the program.
(d) The committee shall meet:
(1) at least once each calendar year; and
(2) at the call of the chairperson.
(e) The term of a member of the committee appointed under this section is four (4) years. The term of a member of the committee expires July 1, but a member may continue to serve on the committee until a successor is appointed.
(f) On or before July 1, 2027, and July 1 biennially thereafter, the committee shall submit a report to the executive director of the legislative services agency, in an electronic format under IC 5-14-6, for review by the interim committee on government in accordance with IC 1-1-15.5-4 and IC 2-5-1.3-13(g). The report shall describe:
(1) official action taken; and
(2) actionable items considered;
by the committee during the preceding two (2) years.
As added by P.L.51-2019, SEC.8. Amended by P.L.56-2023, SEC.242; P.L.161-2025, SEC.28.
Ind. Code § 25-26-24-25 Violations
Sec. 25. A person who knowingly or intentionally releases confidential information in an unauthorized manner violates this chapter and commits a Class A misdemeanor.
As added by P.L.51-2019, SEC.8.
Ind. Code § 25-26-24-26 Rules transferred
Sec. 26. Any administrative rule adopted under IC 35-48-7-12.1 (before its repeal) is hereby considered to be adopted under section 22 of this chapter.
As added by P.L.246-2019, SEC.22 and P.L.264-2019, SEC.11.
Source: Open US Law by Vaquill AI (CC BY 4.0)URL: https://iga.in.gov/laws/2026/ic/titles/25Fetched: 10/17/2026